Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 12, 2016, Pages

  Mbuagbaw, Lawrence ^a,b   Mursleen, Sara ^b   Irlam, James H ^c   Spaulding, Alicen B ^d   Rutherford, George W ^e   Siegfried, Nandi ^f,g  

^a YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Tobacco and Other Drug Research Unit ^*  (South Africa)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; EFAVIRENZ; NEVIRAPINE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; MENTAL FUNCTION; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; ADULT; COMBINATION DRUG THERAPY; DRUG EFFECTS; HIV INFECTIONS; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY; DRUG COMBINATION; METHODOLOGY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NEVIRAPINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 79952199381     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004246.pub4     Document Type: Review

References (73)

1. Ayala Gaytán JJ, Zapata de La Garza ER, Chávez García M, Valdovinos Chávez SB. [Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naïve patients]. Medicina Interna de México 2004;20(1):24-33. [2811951; CN-00641209]
2. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infectious diseases 2013;13(4):303-12. [2811953; PUBMED: 23433590]
3. Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, et al. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antiviral Therapy 2014;19(1):51-9. [2811955; PUBMED: 23970206]
4. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clinical Infectious Diseases 2009;48(12):1752-9. [2811957; PUBMED: 19438397]
5. Mateelli A, Kouanda S, Saleri N, Ouedraogo G. Efficacy and safety of nevirapine- vs efavirenz based ART in TB/HIV patients in Burkina Faso: a clinical and pharmacokinetic study. 20th Conference on Retroviruses and Opportunistic Infections. 3-16 March, 2013. Atlanta, USA, 2013:Abstract 47462. [2811959]
6. Núñez M, Soriano V, Martin-Carbonero L, Barrios A, Barreiro P, Blanco F, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naïve individuals. HIV Clinical Trials 2002;3(3):186-94. [2811961; PUBMED: 12032877]
7. Sinha S, Raghunandan P, Chandrashekhar R, Sharma SK, Kumar S, Dhooria S, et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and tuberculosis infections in India: a pilot study. BMC Infectious Diseases 2013;13:482. [2811963; PUBMED: 24134449]
8. Sow PG, Badiane M, Diallo PD, Lo I, Ndiaye B, Gaye AM. Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivudine+zidovudine+nevirapine in treatment HIV1 infected patients. A cross study analysis [Abstract CDB0584]. XVI International AIDS Conference; 13-18 August, 2006. Toronto, Canada, 2006. [2811965]
9. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clinical infectious disease 2011;53(7):716-724. [2811967]
10. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clinical Trials 2008;9(5):324-36. [2811969; PUBMED: 18977721]
11. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363(9417):1253-63. [2811971; PUBMED: 15094269]
12. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS (London, England) 2010;24 Suppl 1:S27-36. [2811973; PUBMED: 20023437]
13. Antela A, Iribarren JA, Mahillo B, Santos I, Ribera E, Gutierrez C, et al. Final analysis of a prospective, randomized, open-label, multicentre trial in naïve, HIV-1-infected patients, comparing ZDV/3TC vs d4T/ddI, plus efavirenz, nevirapine or indinavir/ritonavir (AMADEUS 01 study). International Conference on AIDS; 11-16 July, 2004; Bangkok, Thailand. 2004; Vol. 15:Abstract no. B11920. [2811975]
14. Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS (London, England) 2008;22(3):367-76. [2811977; PUBMED: 18195563]
15. Bonnet M, Baudin E, Jani IV, Nunes E, Verhoustraten F, Calmy A, et al. Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome. PLOS ONE 2013;8(12):e84585. [2811979; PUBMED: 24367678]
16. Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. European Journal of Medical Research 2008;13(7):343-8. [2811981]
17. de Beaudrap P, Etard JF, Guèye FN, Guèye M, Landman R, Girard PM, et al. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Research and Human Retroviruses 2008;24(6):753-60. [2811983; DOI: 10.1089/aid.2007.0295]
18. Han XX, Zhang M, Cui WG, Liu BG, Wang Y, Zhang ZN, et al. Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China. Zhonghua Yi Xue Za Zhi 2005;85(11):760-4. [2811985]
19. Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). International Journal of STD & AIDS 2005;16(6):404-9. [2811987; PUBMED: 15969773]
20. Hartmann M, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, et al. Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz [Arzneimittelexantheme bei Therapie der HIV-Infektion mit Efavirenz und Nevirapin]. Der Hautarzt 2005;56(9):847-53. [2811989]
21. He Y, Luo Y, Ding YL, Zheng YH, Li J, Huang J, et al. [Effect of highly active anti-retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development]. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine] 2011;45(10):912-5. [2811993; PUBMED: 22321592]
22. Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, et al. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. International Journal of Infectious Diseases 2008;12(6):e33-8. [2811995; PUBMED: 18573672]
23. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. Journal of Acquired Immune Deficiency Syndromes 2004;35(5):492-502. [2811997]
24. Manfredi R, Calza L, Chiodo F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clinical Trials 2005;6(6):302-11. [2811999]
25. Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. AIDS 2006;20(17):2233-6. [2812001]
26. Mankhatitham W, Lueangniyomkul A, Manosuthi W. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian Journal of Tropical Medicine and Public Health 2011;42(3):651-8. [2812003; PUBMED: 21706943]
27. Mankhatitham W, Luaengniyomkul A, Manosuthi W. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy. Chotmaihet thangphaet [Journal of the Medical Association of Thailand] 2012;95(2):163-9. [2812005; PUBMED: 22435244]
28. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection. HIV Medicine 2004;5(2):105-9. [2812007]
29. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Prommool V, Likanonsakul S, et al. Serial monitoring of drug concentrations while on and off rifampicin between standard doses of nevirapine based and efavirenz-based antiretroviral regimens. HIV Medicine 2009;10(Suppl 2):45-221. [2812009]
30. Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, et al. Differences in body circumferences, skin-fold thicknesses and lipid profiles among HIV-infected African children on and not on stavudine. Journal of the International AIDS Society 2012;15(Suppl 4):18290. [2812011]
31. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaissona RE, Regensberg L, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008;22(16):2117-25. [2812013]
32. Negredo E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, et al. Alteration of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antiviral Therapy 2004;9(6):889-93. [2812015]
33. Padmapriyadarsini C, Bhavani PK, Tang A, Kumar H, Ponnuraja C, Narendran G, et al. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. International Journal of Infectious Diseases 2013;17(12):e1154-9. [2812017; PUBMED: 24120216]
34. PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3trial. Lancet Infect Diseases 2011;11(4):273-83. [2812019]
35. Prendergast A, Bwakura-Dangarembizi MF, Cook AD, Bakeera-Kitaka S, Natukunda E, Nahirya Ntege P, et al. Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. AIDS 2011;25(7):951-6. [2812021; PUBMED: 21487251]
36. Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less. Pediatric Infectious Disease Journal 2009;28(3):246-8. [2812023; PUBMED: 19165130]
37. Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatric Infectious Disease Journal 2009;28(6):488-92. [2812025]
38. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Once-daily nevirapine vs efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial. 16th conference on retroviruses and opportunistic infections. Montreal, Canada, February 8-11, 2009. 2009. [2812027; PUBMED: 21890776]
39. Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). International Journal of STD & AIDS 2008;19(5):297-304.
40. BHIVA Writing Committee, BHIVA Executive Committee. Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001;2(4):276-313.
41. Chou R, Rongwei F, Huffman LH, Korthuis PT Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006;368(9546):1503-15.
42. Cooper CL, van Heeswijk RPG. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Medicine 2007;8(1):1-7.
43. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndromes 2001;26 Suppl 1:S25-33.
44. Department of Health and Human Sciences. AIDSinfo Drug Database. https://aidsinfo.nih.gov/drugs/116/nevirapine/0/professional (accessed 10 November 2016).
45. Department of Health and Human Sciences. AIDSinfo Drug Database. https://aidsinfo.nih.gov/drugs/269/efavirenz/0/professional (accessed 10 November 2016).
46. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Morbidity and Mortality Weekly Report 2002;51(RR-7):1-55.
47. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629-34. [PUBMED: 9310563]
48. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368(9534):505-10.
49. GRADE Working Group, McMaster University. GRADEpro GDT. Version (assessed 03 November 2016). Hamilton (ON): GRADE Working Group, McMaster University, 2014.
50. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
51. Higgins JPT, Green S, editor(s) In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008.
52. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349(9061):1294.
53. Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. International Journal of Infectious Diseases 2014;25:130-5. [PUBMED: 24911886]
54. Lau B, Gange S, Kirk G, Mehta S, Merriman B, Moore R. Predictive value of plasma HIV RNA levels for rate of CD4 decline and clinical disease progression. 14th Conference on Retroviruses and Opportunistic Infections (CROI); 25-28 February, 2007; Los Angeles, California. 2007, issue Abstract 140 (oral).
55. Mellors J, Margolick J, Phair J, Rinaldo C, Detels R, Jaconson L, et al. Comparison of plasma HIV-1 RNA, CD4 cell count, and CD38 expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline among untreated participants in the multicenter AIDS cohort study. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February, 2007; Los Angeles, California. 2007.
56. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352(9142):1725-30.
57. Moyle GJ. Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection. Current Opinion in Infectious Diseases 2000;13(1):19-25.
58. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Table for Grading the Severity of Adult and Pediatric Adverse Events. Bethesda, Maryland: National Institutes of Health, 2004.
59. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLOS ONE 2013;8(7):e68995. [PUBMED: 23894391]
60. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
61. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (London, England) 2013;27(9):1403-12. [PUBMED: 23343913]
62. Siegfried NL, Van Deventer PJU, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004535.pub2]
63. UNAIDS AIDS by the numbers 2015. http://www.unaids.org/sites/default/files/media_asset/AIDS-by-the-numbers-2016_en.pdf (accessed 03 November 2016).
64. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15(9):1089-95.
65. World Health Organization. Scaling up antiretroviral therapy in low in resource-limited settings. Guidelines for a public health approach. June 2002. http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf (accessed 03 November 2016).
66. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. http://whqlibdoc.who.int/publications/2006/9789241594677_eng.pdf (accessed 25 September 2008).
67. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 2009. http://www.who.int/hiv/pub/arv/rapid_advice:art.pdf (accessed 03 November 2016).
68. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. July 2014. http://www.who.int/hiv/pub/guidelines/keypopulations/en/ (accessed 09 September 2016).
69. World Health Organization. WHO Model List of Essential Medicines. 19th List. http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1 (accessed 10 September 2008).
70. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. http://www.who.int/hiv/pub/arv/arv-2016/en/ (accessed 03 November 2016).
71. Mbuagbaw LC, Irlam JH. Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD004246.pub2]
72. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD004246.pub3]
73. Neuwelt MD. Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD004246]